Gastrointestinal solid tumors: cross-border specialty drug access for international patients
Oncology
ICD-10: C15-C26
Quick orientation
GI cancers collectively are among the most common cancer groups globally. Colorectal cancer alone has approximately 1.9 million new cases per year worldwide (Globocan 2022).
Typical age of onset. Most commonly diagnosed after age 50; some hereditary forms present earlier.
Severity tiers. Severity depends on stage and molecular profile.
Why specialty drugs for Gastrointestinal solid tumors are hard to access internationally
Several recent FDA approvals for KRAS G12C, BRAF, HER2, and MMR/MSI-high disease have transformed practice. International registration is uneven, particularly for molecularly-defined indications.
Treatments approved by the FDA
- Krazati (adagrasib) — FDA approval: 2022. Mechanism: KRAS G12C inhibitor. Route: Oral twice daily. US WAC ballpark: Approximately USD 230,000 per year. Country pricing: Saudi Arabia · Kuwait · Egypt · Jordan.
- Fruzaqla (fruquintinib) — FDA approval: 2023. Mechanism: Selective VEGFR1/2/3 inhibitor for refractory metastatic colorectal cancer. Route: Oral. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: UAE · India · Qatar · Egypt · Oman.
- Enhertu (trastuzumab deruxtecan) — FDA approval: 2019. Mechanism: HER2-directed antibody-drug conjugate (HER2-positive GI cancer indications). Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt · Oman.
- Ziihera (zanidatamab-hrii) — FDA approval: 2024. Mechanism: HER2-directed bispecific for HER2-positive biliary tract cancer. Route: Intravenous infusion every 2 to 3 weeks. US WAC ballpark: Approximately USD 230,000 per year. Country pricing: Saudi Arabia · Bahrain.
- Vyloy (zolbetuximab) — FDA approval: 2024. Mechanism: Claudin 18.2-directed monoclonal antibody for CLDN18.2-positive gastric/GEJ adenocarcinoma. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: UAE · Saudi Arabia · India · Qatar · Kuwait · Egypt · Bahrain · Lebanon.
Cross-border pathways used for Gastrointestinal solid tumors
Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:
What your physician needs to know
- Confirm molecular profile (KRAS, BRAF, HER2, CLDN18.2, MSI/MMR).
- Document prior systemic therapy.
- Multidisciplinary GI oncology team co-manages.
- Watch for class-specific adverse events.
- Plan supportive care.
Common questions
How is molecular testing handled?
Where local testing is unavailable, samples can be referred to qualified labs.
Are these drugs available in my country?
Registration varies. We confirm by destination.
How long does shipment take?
Five to fifteen business days from prescription receipt.
What documents are required?
Oncologist's prescription, pathology with molecular profile, imaging, and treatment history.
Can targeted therapy be combined with chemotherapy?
Many regimens combine. Your oncologist sets the protocol.
Where Reserve Meds fits in
Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Gastrointestinal solid tumors, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.
We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.
Start a request
Request a drug for Gastrointestinal solid tumors
Reserved for you.